What Adagrasib does

Adagrasib (Adagrasib) is an oral small molecule KRAS inhibitor. KRAS mutations are very common in cancer, accounting for approximately 85% of all RAS family mutations. However, KRAS inhibitors have high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP) and lack a well-defined binding pocket. Adagrasibtargets kras 12c, one of the most common KRAS mutations, located at cysteine u200bu200b12 residue, and inhibits KRAS-dependent signaling. In a Phase I/IB clinical study, adagrasib was effective without new safety signals in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).